MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1181-1187

  Jasinski, Piotr ^a,b   Zwolak, Pawel ^a   Terai, Kaoru ^a   Vogel, Rachel Isaksson ^c   Borja Cacho, Daniel ^a   Dudek, Arkadiusz Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

AURKA; MT477; NRF2; Tumor growth

Indexed keywords

AURKA KINASE; GLUCOCORTICOID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; PHOSPHOTRANSFERASE; PROTEIN P53; QUINOLINE DERIVATIVE; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THIOPYRANO[2,3 C]QUINOLINE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANONICAL ANALYSIS; CELL CYCLE PROGRESSION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NF-E2-RELATED FACTOR 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; QUINOLINES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956067733     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jasinski P, Welsh B, Galvez J, Land D, Zwolak P, Ghandi L, Terai K and Dudek AZ: A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. Invest New Drugs 26(3): 223-232, 2008. (Pubitemid 351579683)
2. Jasinski P, Zwolak P, Terai K and Dudek AZ: Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. Transl Res 152(5): 203-212, 2008.
3. Jasinski P, Zwolak P, Terai K, Borja-Cacho D and Dudek AZ: PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis. Invest New Drugs 29(1): 33-40, 2009.
4. D'Argenio D: Adapt II User's Guide: Pharmacokinetic/ Pharmacodynamic System Analysis Software. Biomedical Simulations Resource: Los Angeles, CA, USA, 1997.
5. Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM and Saluja AK: Triptolide induces pancreatic cancer cell death via inhibition of heat-shock protein 70. Cancer Res 67(19): 9407-9416, 2007. (Pubitemid 47535931)
6. Llompart J, Galvez J and Pal K: US Patent 20060014770. Patent/Therapeutic Compound and Treatments, 2006.
7. Li W and Kong AN: Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 48(2): 91-104, 2009.
8. Lyakhovich VV, Vavilin VA, Zenkov NK and Menshchikova EB: Active defense under oxidative stress. The antioxidant responsive element. Biochemistry (Mosc) 71(9): 962-974, 2006.
9. Sankaranarayanan K and Jaiswal AK: Nrf3 negatively regulates antioxidant-response element-mediated expression and antioxidant induction of NAD(P)H: quinone oxidoreductase1 gene. J Biol Chem 279(49): 50810-50817, 2004. (Pubitemid 40017819)
10. Schaaf MJ and Cidlowski JA: Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 83(1-5): 37-48, 2002. (Pubitemid 37040640)
11. Barnes PJ: Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 94(6): 557-572, 1998.
12. Menendez D, Inga A and Resnick MA: The expanding universe of p53 targets. Nat Rev Cancer 9(10): 724-737, 2009.
13. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW and Vogelstein B: Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 96(25): 14517-14522, 1999. (Pubitemid 30000682)
14. Wang K, Chen S, Xie W and Wan YJ: Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem Pharmacol 75(11): 2204-2213, 2008.
15. Guengerich FP: Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21(1): 70-83, 2008.
16. O'Shea JJ, Gadina M and Schreiber RD: Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl): S121-S131, 2002.
17. Hu MC, Qiu WR and Wang YP: JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene 15(19): 2277-2287, 1997.
18. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298(5600): 1911-1912, 2002.
19. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR and Landvatter SW: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372(6508): 739-746, 1994.
20. Barsyte-Lovejoy D, Galanis A and Sharrocks AD: Specificity determinants in MAPK signaling to transcription factors. J Biol Chem 277(12): 9896-9903, 2002. (Pubitemid 34968095)
21. Carling D: The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 29(1): 18-24, 2004.
22. Long YC and Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116(7): 1776-1783, 2006.
23. Rivero-Lezcano OM, Marcilla A and Robbins KC: Mutations in the non-catalytic domains of Fyn and Fgr tyrosine kinases reveal differences in mechanisms of their regulation. Oncogene 11(12): 2675-2679, 1995. (Pubitemid 26023836)
24. Tronick SR, Popescu NC, Cheah MS, Swan DC, Amsbaugh SC, Lengel CR, DiPaolo JA and Robbins KC: Isolation and chromosomal localization of the human FGR protooncogene, a distinct member of the tyrosine kinase gene family. Proc Natl Acad Sci USA 82(19): 6595-6599, 1985. (Pubitemid 16228866)
25. Dar AA, Goff LW, Majid S, Berlin J and El-Rifai W: Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther 9(2): 268-278, 2010.
26. Berdnik D and Knoblich JA: Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Curr Biol 12(8): 640-647, 2002. (Pubitemid 34315847)
27. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E and Saya H: Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 278(51): 51786-51795, 2003.
28. Dar AA, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A, Washington K, Castells A, Pera M and El-Rifai W: Frequent overexpression of Aurora kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 112(8): 1688-1698, 2008. (Pubitemid 351536828)
29. Crane R, Gadea B, Littlepage L, Wu H and Ruderman JV: Aurora A, meiosis and mitosis. Biol Cell 96(3): 215-229, 2004. (Pubitemid 38461446)